Results 311 to 320 of about 133,417 (336)
Some of the next articles are maybe not open access.
Prodrugs in Genetic Chemoradiotherapy
Current Pharmaceutical Design, 2003Improvements in the radiotherapeutic management of solid tumors through the concurrent use of gene therapy is a realistic possibility. Of the broad array of candidate genes that have been evaluated, those encoding prodrug-activating enzymes are particularly appealing since they directly complement ongoing clinical chemoradiation regimes.
Adam V. Patterson +2 more
openaire +3 more sources
Chemoradiotherapy for cervical cancer
European Journal of Cancer, 2002Cervical cancer remains a major health problem worldwide, despite advances in screening. For patients with locally advanced stage disease, failure to obtain local-regional control usually results in death. In an effort to improve local-regional tumour control, neoadjuvant and concurrent chemoradiation has been tested.
openaire +3 more sources
Radiotherapy and Chemoradiotherapy
2018Neoadjuvant radiation therapy or chemoradiotherapy followed by surgery has the potential to improve patient survival by reducing the risk of locoregional and distant metastasis of gastric cardiac cancer in both thoracic and abdominal organs. Because of the limited case number in prior clinical trials on the efficacy of radiation or chemoradiotherapy ...
Xingchu Ni, Kun (Kim) Huang
openaire +2 more sources
Chemoradiotherapy for cancer of the cervix
Journal of Clinical Oncology, 20055183 Background: Cancer of the cervix continues to be the most frequent neoplastic disease in Mexico. Most cases are detected in Stage II and III.
J. L. Gonzalez Vela +8 more
openaire +2 more sources
Chemotherapy and Chemoradiotherapy
2014There are various roles of chemotherapy for the treatment of esophageal squamous cell carcinoma. The standard treatment for metastatic esophageal cancer has been 5-FU and cisplatin for decades. Recently, taxanes and targeted therapies are on the way of development.
openaire +2 more sources
Chemoradiotherapy for lung cancer
Expert Opinion on Pharmacotherapy, 2005Chemoradiotherapy is a standard treatment for both unresectable locally advanced non-small cell lung cancer and limited-stage small cell lung cancer. Cisplatin-based chemotherapy with concurrent thoracic radiotherapy yields a 5-year survival rate of approximately 15% for patients with unresectable locally advanced non-small cell lung cancer.
openaire +3 more sources
Chemotherapy and chemoradiotherapy for esophageal cancer
Critical Reviews in Oncology/Hematology, 1998Carcinoma of the esophagus is a highly virulent disease. Although surgery has generally been considered the standard therapy for local regionally confined esophageal cancer, the results remained poor with 5year survivals of 6–24% in Western countries [1]. In the results of a Japanese nationwide registration, the overall 5-year survival rate of resected
Atsushi Ohtsu, Shigeaki Yoshida
openaire +3 more sources
Preoperative chemoradiotherapy for carcinoma of the vulva
Gynecologic Oncology, 1981Abstract We report the case of a 71-year-old woman with advanced squamous carcinoma of the vulva who achieved marked tumor regression following therapy with 5-fluorouracil and mitomycin combined with preoperative radiotherapy. The patient underwent radical vulvectomy.
Sidney S. Chen +7 more
openaire +3 more sources
Chemoradiotherapy in the treatment of rectal cancer
Hematology/Oncology Clinics of North America, 2002The integration of radiotherapy to the adjuvant treatment of rectal cancer was prompted by the predominance of locoregional failures after curative surgery. This characteristic in the pattern of failure is one of the main reasons adjuvant radiotherapy plays a greater role in rectal cancer than in colon cancer.
James M. Metz +2 more
openaire +3 more sources
Rectal cancer: Neoadjuvant chemoradiotherapy
Best Practice & Research Clinical Gastroenterology, 2016The monolithic approach to apply the same schedule of preoperative 5-fluorouracil (5-FU)- or capecitabine-based chemoradiotherapy (CRT) to all patients with clinically staged TNM stage II/III rectal cancer need to be questioned. Five randomized trials have been completed to determine if the addition of oxaliplatin to preoperative 5-FU/capecitabine ...
Emmanouil Fokas +4 more
openaire +3 more sources